Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

S

Paris RM, Petrovas C, Ferrando-Martinez S, et al. "Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression." PLoS ONE. 2015;10(12):e0144767.
Schifitto G, Yiannoutsos CT, Ernst T, et al. "Selegiline and oxidative stress in HIV-associated cognitive impairment." Neurology. 2009;73(23):1975-81.
Evans SR, Yeh T-min, Sacktor N, et al. "Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090." HIV Clin Trials. 2007;8(6):437-46.
Delahunty T, Bushman L, Fletcher CV. "Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS." J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2006;830(1):6-12.
Butler DM, Smith DM. "Serosorting can potentially increase HIV transmissions." AIDS. 2007;21(9):1218-20.
Hogan CM, Degruttola V, Sun X, et al. "The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals." J. Infect. Dis.. 2012;205(1):87-96.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Umeh OC, Currier JS, Park J-G, Cramer Y, Hermes AE, Fletcher CV. "Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men." J Clin Pharmacol. 2011;51(12):1665-73.
Meier A, J Chang J, Chan ES, et al. "Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1." Nat. Med.. 2009;15(8):955-9.
Grinsztejn B, Smeaton L, Barnett R, et al. "Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count." Antivir. Ther. (Lond.). 2011;16(7):1057-62.
Mathad JS, Gupte N, Balagopal A, et al. "Sex-related Differences in Inflammatory and Immune Activation Markers before and after combined Antiretroviral Therapy Initiation." J. Acquir. Immune Defic. Syndr.. 2016.
Chow D, Chen H, Glesby MJ, et al. "Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients." AIDS. 2009;23(16):2133-41.
Yuste E, Sanford HB, Carmody J, et al. "Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma." J. Virol.. 2006;80(6):3030-41.
Akpa O, Miyahara S, Taiwo B, Evans S, Berzins B, Robertson K. "Similar changes in neuropsychological functioning in english and spanish speaking HIV patients." Brain Behav. 2018;8(9):e01083.
Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. "Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)." Open Forum Infect Dis. 2018;5(6):ofy103.
Evans SR, Clifford DB, Kitch DW, et al. "Simplification of the research diagnosis of HIV-associated sensory neuropathy." HIV Clin Trials. 2008;9(6):434-9.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Li JZ, Etemad B, Ahmed H, et al. "The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption." AIDS. 2016;30(3):343-53.
Naggie S, Marks KM, Hughes M, et al. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." Clin. Infect. Dis.. 2017;64(8):1035-1042.
Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AMarie. "Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332." Medicine (Baltimore). 2018;97(22):e10955.
Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AMarie, Aberg JA. "Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332." Inflammation. 2016;39(4):1354-62.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Hoenigl M, Moser C, Funderburg N, et al. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression." Clin. Infect. Dis.. 2018.
Sieg SF, Bazdar DA, Lederman MM. "S-phase entry leads to cell death in circulating T cells from HIV-infected persons." J. Leukoc. Biol.. 2008;83(6):1382-7.
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. "Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort." Antivir. Ther. (Lond.). 2009;14(6):853-8.
Liu D, Yu J, Chen H, Reichman R, Wu H, Jin X. "Statistical determination of threshold for cellular division in the CFSE-labeling assay." J. Immunol. Methods. 2006;312(1-2):126-36.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Chow FC, Wilson MR, Wu K, Ellis RJ, Bosch RJ, Linas BP. "Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort." AIDS. 2018;32(9):1125-1135.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.

Pages